Cocaine Use Reduction with Buprenorphine (CURB): Rationale, design, and methodology

March 2, 2016

Conclusions: This research using 2 medications will demonstrate whether BUP, administered in the presence of XR-NTX, reduces cocaine use in adults with cocaine dependence and opioid use disorders and will demonstrate if XR-NTX prevents development of physiologic dependence on BUP. (Source: Contemporary Clinical Trials) MedWorm Sponsor Message: Directory of the best January Sales in the […]

Read the full article →

Contingency management is efficacious in opioid-dependent outpatients not maintained on agonist pharmacotherapy.

March 2, 2016

Contingency management (CM) is an empirically supported intervention for substance dependence, but it has not been evaluated systematically in non maintained opioid-dependent patients. This retrospective analysis examined whether CM was effective in opioid-dependent patients initiating intensive outpatient psychosocial treatment. In the primary trial (Petry, N. M., Weinstock, J., & Alessi, S. M. [2011]. A randomized […]

Read the full article →

Initiation of buprenorphine during incarceration and retention in treatment upon release

March 2, 2016

We report here on a feasibility study of initiating buprenorphine/naloxone prior to release from incarceration and linking participants to community treatment providers upon release. The study consisted of a small number of Rhode Island (RI) prisoners (N=44) diagnosed with opioid dependence. The study design is a single arm, open-label pilot study with a 6-month follow […]

Read the full article →

First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland

March 2, 2016

Conclusion: Provision of buprenorphine-naloxone in Finnish community pharmacies has remained relatively small-scale. As experiences have been generally positive and problems rare, it may be possible to expand these services. (Source: International Journal of Drug Policy)

Read the full article →

BUPRENORPHINE HCL AND NALOXONE HCL (Buprenorphine And Naloxone) Tablet [AvKARE, Inc.]

March 2, 2016

Updated Date: Apr 16, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

Jennifer Serrentino, M.D. Recently Launches a Blog Post Discussing the…

March 2, 2016

Well known local psychiatrist, Jennifer Serrentino, M.D., recently discusses the Suboxone controversy on her blog.(PRWeb April 19, 2013)Read the full story at http://www.prweb.com/releases/Local-Port-Jefferson/Psychiatrist-Jennifer-Ser/prweb10636625.htm (Source: PRWeb: Medical Pharmaceuticals) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Pain and Associated Substance Use among Opioid Dependent Individuals Seeking Office-Based Treatment with Buprenorphine-Naloxone: A Needs Assessment Study.

March 2, 2016

CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: The high rates of pain and self-reported substance use to manage pain suggest the importance of assessing and addressing pain in BNT patients. (Am J Addict 2013; 22:212-217). PMID: 23617861 [PubMed – in process] (Source: American Journal on Addictions)

Read the full article →

Buprenorphine + Naloxone in the Treatment of Opioid Dependence during Pregnancy-Initial Patient Care and Outcome Data.

March 2, 2016

CONCLUSIONS: Findings suggest no obvious significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy. SCIENTIFIC SIGNIFICANCE: These initial findings underscore the need for future research to systematically examine the relative safety and effectiveness of buprenorphine + naloxone for mother, fetus, and child. (Am J Addict 2013; […]

Read the full article →

Novel Opioid Dependence Pill Gets Patients' Thumbs-UpNovel Opioid Dependence Pill Gets Patients' Thumbs-Up

March 2, 2016

Compared with buprenorphine-naloxone sublingual film to treat opioid dependence, a sublingual menthol-flavored tablet has a preferred taste and comparable dissolve time. Medscape Medical News (Source: Medscape Today Headlines)

Read the full article →

Acute Pain Control Challenges with Buprenorphine/Naloxone Therapy in a Patient with Compartment Syndrome Secondary to McArdle's Disease: A Case Report and Review

March 2, 2016

We report the first case of non‐iatrogentic exertional rhabdomyolysis leading to acute compartment syndrome in a patient with McArdle’s disease. We describe considerations of concurrent buprenorphine/naloxone therapy during episodes of severe acute pain. DesignCase report. Case PresentationA 50‐year‐old male with a history of McArdle’s disease, taking buprenorphine/naloxone for chronic pain and opioid dependence, presented to […]

Read the full article →

← Previous Entries

Next Entries →